Literature DB >> 10874596

Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis.

T Tsurukai1, N Udagawa, K Matsuzaki, N Takahashi, T Suda.   

Abstract

We have isolated osteoclast precursors (OCPs) from cocultures of mouse calvarial cells and bone marrow cells without adding any osteotropic factors. OCPs expressed Mac-1, Mac-2, and Gr-1 antigens but not osteoclast markers such as tartrate-resistant acid phosphatase (TRAP) and calcitonin receptors, and they differentiated into TRAP-positive cells within 48 h on a fixed calvarial cell layer pretreated with osteotropic factors such as 1 alpha, 25-dihydroxyvitamin D3. In the present study, we investigated the regulatory mechanisms of OCP formation from hemopoietic cells and TRAP-positive cell formation from OCPs. Calvarial osteoblasts obtained from macrophage-colony stimulating factor (M-CSF)-deficient op/op mice failed to support OCP formation or the differentiation of OCPs into TRAP-positive cells. Both OCP formation and TRAP-positive cell formation supported by osteoblasts were completely inhibited by osteoclastogenesis inhibitory factor (OCIF, also called OPG), which is a decoy receptor of osteoclast differentiation factor (ODF; also called TRANCE, RANKL, and OPGL). When bone marrow cells were cultured for 4 days with soluble ODF (sODF/sRANKL) together with M-CSF, OCPs were formed even in the absence of osteoblasts. When OCPs were treated with sODF/sRANKL and M-CSF in the absence of osteoblasts, they differentiated into TRAP-positive cells within 48 h even in the presence of hydroxyurea. Northern blotting analysis revealed that osteoblasts constitutively expressed a certain level of ODF/RANKL mRNA. These results indicated that M-CSF and sODF/sRANKL produced by osteoblasts are two essential factors for both OCP formation and TRAP-positive osteoclast formation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10874596     DOI: 10.1007/s007740070018

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  27 in total

1.  The majority of the genetic risk for Paget's disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes.

Authors:  Pui Yan Jenny Chung; Greet Beyens; Steven Boonen; Socrates Papapoulos; Piet Geusens; Marcel Karperien; Filip Vanhoenacker; Leon Verbruggen; Erik Fransen; Jan Van Offel; Stefan Goemaere; Hans-Georg Zmierczak; René Westhovens; Jean-Pierre Devogelaer; Wim Van Hul
Journal:  Hum Genet       Date:  2010-09-14       Impact factor: 4.132

2.  Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells.

Authors:  Suwen Wei; Sayan Nandi; Violeta Chitu; Yee-Guide Yeung; Wenfeng Yu; Minmei Huang; Lewis T Williams; Haishan Lin; E Richard Stanley
Journal:  J Leukoc Biol       Date:  2010-05-26       Impact factor: 4.962

3.  microRNA Expression in Rat Apical Periodontitis Bone Lesion.

Authors:  Bo Gao; Liwei Zheng
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

4.  Mutation in Osteoactivin Promotes Receptor Activator of NFκB Ligand (RANKL)-mediated Osteoclast Differentiation and Survival but Inhibits Osteoclast Function.

Authors:  Samir M Abdelmagid; Gregory R Sondag; Fouad M Moussa; Joyce Y Belcher; Bing Yu; Hilary Stinnett; Kimberly Novak; Thomas Mbimba; Matthew Khol; Kurt D Hankenson; Christopher Malcuit; Fayez F Safadi
Journal:  J Biol Chem       Date:  2015-04-02       Impact factor: 5.157

Review 5.  Paget disease of bone.

Authors:  G David Roodman; Jolene J Windle
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

Review 6.  Minireview: nuclear receptor regulation of osteoclast and bone remodeling.

Authors:  Zixue Jin; Xiaoxiao Li; Yihong Wan
Journal:  Mol Endocrinol       Date:  2014-12-30

7.  RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease.

Authors:  Tara L Aghaloo; Simon Cheong; Olga Bezouglaia; Paul Kostenuik; Elisa Atti; Sarah M Dry; Flavia Q Pirih; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2014-04       Impact factor: 6.741

Review 8.  Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

Authors:  J L Sottnik; E T Keller
Journal:  Curr Mol Med       Date:  2013-05       Impact factor: 2.222

Review 9.  Osteoclast motility: putting the brakes on bone resorption.

Authors:  Deborah V Novack; Roberta Faccio
Journal:  Ageing Res Rev       Date:  2009-09-27       Impact factor: 10.895

10.  Stage-dependent suppression of the formation of dentin-resorbing multinuclear cells with migration inhibitory factor in vitro.

Authors:  Takashi Kikuiri; Yoshitaka Yoshimura; Futoshi Tabata; Tomokazu Hasegawa; Jun Nishihira; Tetsuo Shirakawa
Journal:  Exp Ther Med       Date:  2011-10-07       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.